Firm developing rapid gonorrhea test wins $19M prize

By LabPulse.com staff writers

August 6, 2020 -- A company developing a rapid diagnostic test for the microorganism that causes gonorrhea has won $19 million in a challenge that's part of the U.S. government's Antimicrobial Resistance Diagnostic Challenge.

Visby Medical won the prize for its patient-side, disposable, molecular polymerase chain reaction (PCR) diagnostic device that detects Neisseria gonorrhoeae as well as markers of drug resistance. The device is a palm-sized, single-use, disposable device that detects N. gonorrhoeae and can determine whether the bacteria is susceptible to a single-dose antibiotic.

Colorized scanning electron micrograph of Neisseria gonorrhoeae bacteria
Colorized scanning electron micrograph of Neisseria gonorrhoeae bacteria, which causes gonorrhea. Image courtesy of the U.S. National Institute of Allergy and Infectious Diseases.

This type of rapid testing that includes assessment of antibiotic susceptibility has not been available previously as a point-of-care diagnostic device. The Visby device could be useful in ensuring that patients with gonorrhea receive the appropriate antibiotic so that they can immediately begin treatment. It will also allow other antibiotics to be used for patients with drug-resistant strains of N. gonorrhoeae if it is approved by the U.S. Food and Drug Administration.

Co-sponsored by the U.S. National Institutes of Health (NIH) and the Biomedical Advanced Research and Development Authority (BARDA) of the Health and Human Services Office of the Assistant Secretary for Preparedness and Response, the challenge encourages companies to come up with technologies that can reduce unnecessary use of antibiotics, which drives antibiotic resistance.

New POC test performs well for chlamydia, gonorrhea in women
A rapid point-of-care (POC) test for chlamydia and gonorrhea demonstrated excellent performance in women and good performance in men in a comparative...
Binx point-of-care STI test cleared for men
Binx Health's point-of-care binx io molecular diagnostic instrument enabling rapid testing and reporting of sexually transmitted infections (STIs) has...
Binx point-of-care STI testing clears FDA
Binx Health's point-of-care binx io molecular diagnostic instrument enabling rapid testing and reporting of sexually transmitted infections (STIs) in...
SpeeDx gonorrhea test gets breakthrough status in U.S.
The ResistancePlus GC test from SpeeDx for detecting Neisseria gonorrhoeae bacteria has received breakthrough device designation from the U.S....
STD test market grows with incidence, new tech
The need to make screening and testing of sexually transmitted diseases (STDs) more accessible worldwide is creating opportunities for manufacturers of...

Copyright © 2020 LabPulse.com

Last Updated ls 8/5/2020 5:25:58 PM



Subscribe Today
Do you want to be a Microbiology Insider?

When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.

Yes, Keep Me Current